January 1, 1999Thrombosis and Haemostasis
A Whole Blood Assay of Inhibition of Platelet Aggregation by Glycoprotein IIb/IIIa Antagonists: Comparison with other Aggregation Methodologies
View Full Paper
Ask AI
Bookmark
Share
Why the study?
Does a whole blood single-platelet counting assay accurately measure platelet aggregation inhibition by GPIIb/IIIa antagonists compared to other methodologies in patients with unstable angina?
Population
8 patients with unstable angina (and in vitro blood samples)
Comparison
Oral lefradafiban and fradafiban vs Placebo (for patients)
Design
RCT, randomised
Follow-up
during treatment
Authors
Discussion
Loading...
Member takes
Implication
Supports WBSPC for rapid high-level GPIIb/IIIa monitoring in unstable angina; extends platelet assay validation in RCT.
Structured PICO
Does a whole blood single-platelet counting assay accurately measure platelet aggregation inhibition by GPIIb/IIIa antagonists compared to other methodologies in patients with unstable angina?
P
Population
8 patients with unstable angina (and in vitro blood samples)
I
Intervention
Oral lefradafiban (for patients) and fradafiban (in vitro)
C
Comparator
Placebo (for patients)
O
Outcome
Platelet aggregation inhibition measured by whole blood single-platelet counting assay (WB-SPC) compared to PRP turbidimetry, impedance aggregometry, and Rapid Platelet Function Assaysurrogate
The whole blood single-platelet counting assay is a rapid and discriminating method for monitoring high levels of GPIIb/IIIa antagonist effect.
Cite This Study
Storey et al. (1999) studied this question.
Topics
View Full Paper
Ask AI
Bookmark
Share